semaglutide and menopause GLP-1s, Obesity, Menopause: Benefits and Risks Women turn to weight loss

Maintaining metabolic variety and addressing potential contributing factors reduces the likelihood of repeated stalls

October 3, 2024: Novo Nordisks New Weight Loss Drug Amycretin Shows Promising Early Results The defendant in the Wegovy lawsuit, Novo Nordisk, has announced that its new weight loss drug, amycretin, has been marked as safe and tolerable for patients

Under clinical investigation, primarily in Asia (Phase 3 in China)

A Game-Changer in Metabolic Medicine

"The fact that semaglutide reduced non-cardiovascular death, and in particular COVID-19-related deaths, was surprising."

Since Ozempic does not cross into breast milk, it should not cause side effects in breastfed infants or affect their health or development, she explains